- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05360732
Redefining FOLFIORINOX in Older Pancreatic Cancer Patients
Redefining The Use Of A FOLFIRINOX-Like Regimen In the Front Line In Older Patients With Metastatic Pancreatic Cancer
Study Overview
Detailed Description
This is a multi-centered two-stage Pilot Study assessing the tolerability and toxicity of an alternating regimen of FOLFOX and FOLFIRI for the treatment of newly diagnosed and untreated metastatic pancreatic cancer in patients over the age of 65 years. Treatment will be given in the outpatient infusion room or clinical research unit. Reported adverse events and potential risks of these agents are described below. No investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's malignancy.
The study will accrue 37 patients who will be evaluated by correlating their daily activity via use of FitBit that will be provided to the patients, blood markers and progression of the disease with the toxicity grades observed during the treatment. Patients will be treated with standard of care doses of all the chemotherapeutic drugs. The study will be analyzed for futility after treatment of 20 patients. Each cycle consists of 28 days during which patient treatment will alternate between FOLFOX and FOLFIRI on day 1 and day 14 respectively. Patients will be treated until disease progression or any of the conditions listed in Section 4.4 that applies. Patient's response to treatment will be evaluated by CT scans every 8 weeks and the tumor will be assessed using RECIST v1.1 criteria.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Tanu singh
- Phone Number: 12152141439
- Email: tanu.singh@fccc.edu
Study Contact Backup
- Name: Efrat Dotan, MD
- Phone Number: 215-214-4283
- Email: efrat.dotan@fccc.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Recruiting
- Fox Chase Cancer Center
-
Contact:
- Efrat Dotan, MD
- Phone Number: 888-369-2427
- Email: Efrat.Dotan@fccc.edu
-
Principal Investigator:
- Efrat Dotan, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 65 years or older
- The treating physician will use their discretion when assessing if the patient is eligible for this treatment.
- Patients must have newly diagnosed and previously untreated, histologically or cytologically confirmed adenocarcinoma of the pancreas, with at least one site of metastatic disease (local recurrences after surgery allowed), with lesions that are measurable by RECIST v1.1 criteria. In patients with mixed histology tumors, the predominant feature must be adenocarcinoma.
- Eastern Cooperative Oncology Group Performance status of 0-2.
- Previous surgery, adjuvant chemotherapy and/or radiation therapy will be allowed, provided radiation therapy is completed at least 2 weeks prior to signing consent and adjuvant therapy was administered more than 6 months prior to signing consent.
Patients must have bone marrow and organ function as defined below:
- Absolute Neutrophil Count ≥ 1,500/μL
- Platelets ≥ 100,000/μL
- Total Bilirubin ≤2 X ULN
AST(SGOT)/ALT(SGPT)/
o Alkaline Phasphatase ≤3 X ULN
o Or ≤5x ULN if liver metastasis present
- Creatinine ≤2.0 mg/dL And
- eGFR (using Cockcroft Gault equation) > 40ml/min
- Patients must be fluent in English and must be able and willing to undergo Comprehensive Geriatric Assessment
- Chemotherapy is harmful to the human fetus. For this reason, sexually active males with partners of childbearing potential must agree to use an accepted and effective method of contraception prior to study entry and for the duration of the study.
- Patients must demonstrate ability to understand and the willingness to sign a written informed consent document.
- Men and women, regardless of race, ethnic group or sexual orientation are eligible for this study.
Exclusion Criteria:
1. Endocrine or acinar pancreatic carcinoma
2 Patients who have had any systemic chemotherapy in the metastatic or locally advanced inoperable setting (adjuvant or neoadjuvant therapy is allowed)
3 Patients who have received radiation therapy within 2 weeks of signing consent.
4 Patients who are currently receiving or have previously received any other investigational therapy for metastatic pancreatic cancer.
5 Patients with known brain metastases - treated or untreated, are excluded from this study because of their poor prognosis and frequent development of progressive neurological dysfunction that would confound the evaluation of neurologic and other adverse events.
6 Any patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, known HIV-positive patients and those with known active or inactive hepatitis B, untreated HCV or treated HCV without a documented sustained virologic response are excluded from the study.
7 Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active bacterial infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
8 Patients with evidence of active malignancy within 2 years of enrollment without definitive treatment. Patients with localized prostate cancer status-post surgical resection or definitive radiation, localized ER/PR+/HER2- breast cancer status-post definitive local treatment with a low OncotypeDx® on adjuvant hormonal therapy, or local skin cancers that were previously resected will be eligible for inclusion. Patients with a history of in situ cancers treated with definitive local therapy will also be eligible.
9 Patients with grade 3 or higher baseline sensory neuropathy
10 Patients with chronic diarrhea (>4 bowel movements/day) unresolved despite best supportive care for greater than 2 weeks.
11 Patients with any of the following results on the Comprehensive Geriatric Assessment:
- >2 falls in the past month
- BMI <18
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: FOLFIRINOX
FOLFIRINOX: Oxaliplatin, Leucovorin and 5-Fluorouracl, Irinotecan,
|
Alternating FOLFOX and FOLFIRI administered via intravenous infusion.
FOLFOX: Oxaliplatin 85 mg/m2 on Day 1; Leucovorin 400 mg/m2 on day 1; 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours.
FOLFIRI: Irinotecan 180 mg/m2 on day 1, leucovorin 400 mg/m2, 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the toxicity profile of a regimen of alternating FOLFOX and FOLFIRI patients assessed as per NCI's CTCAE v5.0 criteria.
Time Frame: 2 months
|
To assess the toxicity profile of a regimen of alternating FOLFOX and FOLFIRI at 2 months in newly diagnosed and untreated metastatic pancreatic adenocarcinoma patients over the age of 65 years deemed ineligible to receive the FOLFIRINOX regimen
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the Progression Free Survival (PFS)
Time Frame: 2 years
|
To assess the Progression Free Survival (PFS) defined as the time from enrollment to disease progression, death or last patient contact, whichever comes first, for up to 2 years from the end of treatment visit.
|
2 years
|
To assess the Overall Survival (OS)
Time Frame: 2 years
|
Overall Survival (OS) is defined as the time from treatment initiation to death due to any cause or overall survival.
Patients will be followed for up to 2 years after the end of treatment visit.
|
2 years
|
To assess the Objective Response Rate (ORR)
Time Frame: 2 years
|
Objective Response Rate (ORR) is defined as the best response in terms of tumor shrinkage measured by RECIST v1.1 criteria obtained during protocol therapy.
|
2 years
|
To assess the Delayed Toxicity Rate
Time Frame: 8 weeks
|
Delayed Toxicity Rate is defined as the absolute percentage of toxicities as measured according toNCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0
|
8 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-1027
- GI-170 (Other Identifier: Fox Chase Cancer Center)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Pancreatic Cancer
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Orion Biotechnology Polska Sp. z o.o.Not yet recruitingMetastatic Colorectal Cancer | Metastatic Cancer | Metastatic Breast Cancer | Metastatic Urothelial Carcinoma | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)CompletedMetastatic Colorectal Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic CancerUnited States
-
Dana-Farber Cancer InstitutePatient-Centered Outcomes Research Institute; National Cancer Institute (NCI); Alliance for Clinical Trials in OncologyCompletedMetastatic Colorectal Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic CancerUnited States
-
University Hospital HeidelbergGerman Cancer Research CenterCompletedColorectal Cancer Metastatic | Pancreatic Cancer MetastaticGermany
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal AdenocarcinomaUnited States
-
HonorHealth Research InstituteUniversity of Arizona; Agenus Inc.; Translational Genomics Research InstituteNot yet recruitingPancreatic Cancer Metastatic | Pancreatic Adenocarcinoma MetastaticUnited States
-
Pancreatic Cancer Action NetworkActive, not recruitingMetastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic CancerUnited States
-
Joachim Aerts, MD PhDCompletedMetastatic Pancreatic CancerNetherlands
-
Georgetown UniversityNational Cancer Institute (NCI); Mayo Clinic; Emory University; Indiana University and other collaboratorsTerminatedMetastatic Colorectal Cancer | Pancreatic Adenocarcinoma | Colorectal Adenocarcinoma | Metastatic Pancreatic CancerUnited States
Clinical Trials on FOLFIRINOX
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedCholangiocarcinomaNetherlands
-
Asan Medical CenterGreen Cross Corporation; Boryung Pharmaceutical Co., LtdRecruitingUrachal CancerKorea, Republic of
-
Instituto do Cancer do Estado de São PauloRecruitingGastric CancerBrazil
-
Institut du Cancer de Montpellier - Val d'AurelleActive, not recruitingMetastatic Colorectal CancerFrance
-
King Faisal Specialist Hospital & Research CenterTerminatedBiliary Tract CancerSaudi Arabia
-
Institut du Cancer de Montpellier - Val d'AurelleRecruitingMetastatic Pancreatic CancerFrance
-
Cantargia ABCompletedMetastatic Pancreatic Ductal AdenocarcinomaSpain, France
-
Azienda Ospedaliero, Universitaria PisanaCompletedPancreatic Cancer Non-resectableItaly
-
The University of Texas Health Science Center,...WithdrawnPancreatic Adenocarcinoma
-
Assiut UniversityUnknown